Biogen Inc

Pharmaceuticals

BIIB

$ 193 (1.5)%

Share price

$ 28 bn

Market Cap

$ 32 bn

Enterprise Value

Carbon footprint

GHG emissions per $ 1 mln investment

0.06x the weighted average for S&P 500

FY2020

Primary Climate Goal

Proj. YOY change in GHG emissions (Scope 1 + 2)

Weaker than the -5.1% weighted average for S&P 500

FY2021

Biogen Inc aims to reduce Scope 1 + 2 by 55% by 2032 from a base year 2019

1.5°C

GHG emissions and Carbon intensity

Biogen Inc reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2020 at 58 Kt (-9.8 /-14.5% y-o-y). Also positively, carbon intensity dropped to 4.3 t (-0.4 /-8.5% y-o-y).

Biogen Inc's Scope 3 emissions declined to 349 Kt (-76 /-17.8% y-o-y). This is a higher rate of decline than over the period since 4Q'17 (-7.8% CAGR).

The company is committed to reducing Scope 1 + 2 by 55% by 2032 from a base year 2019, which translates into the estimated reduction of -2.3 Kt per annum over the period of FY2021 - FY2032. This science-based target is aligned with Paris Agreement to limit global warming to 1.5°C above pre-industrial levels.

Date	Total CO2e emissions (market-based Scope 1 & 2) (Kt)	Scope 1	Scope 2	Scope 3	Revenue (USDm)	Carbon intensity (tons of CO2e) / (USDm)
2020Q4	58	58	0.18	349	13,445	4.3
2019Q4	68	67	0.11	425	14,378	4.7
2018Q4	69	68	0.06	436	13,453	5.1
2017Q4	62	62	0.06	482	12,274	5
2016Q4	62	62	0.16	255	11,449	5.4
2015Q4	60	60	0.19	262	10,764	5.6

Biogen Inc

Carbon footprint

Primary Climate Goal

Biogen Inc aims to reduce Scope 1 + 2 by 55% by 2032 from a base year 2019

GHG emissions and Carbon intensity

Biogen Inc's carbon footprint

Company environmental metrics